4.6 Article

Characterising the association of latency with alpha(1)-antitrypsin polymerisation using a novel monoclonal antibody

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.biocel.2014.11.005

关键词

alpha 1-Antitrypsin; Latency; Polymerisation; Monoclonal antibodies; Augmentation therapy

资金

  1. Medical Research Council (UK)
  2. UCLH BRC
  3. MRC [G0601840, G0901786, G1000277, G1002610] Funding Source: UKRI
  4. Medical Research Council [G1000277, G0601840, G1002610, G0901786] Funding Source: researchfish
  5. National Institute for Health Research [NF-SI-0513-10070] Funding Source: researchfish

向作者/读者索取更多资源

alpha(1)-Antitrypsin is primarily synthesised in the liver, circulates to the lung and protects pulmonary tissues from proteolytic damage. The Z mutant (Glu342Lys) undergoes inactivating conformational change and polymerises. Polymers are retained within the hepatocyte endoplasmic reticulum (ER) in homozygous (PiZZ) individuals, predisposing the individuals to hepatic cirrhosis and emphysema. Latency is an analogous process of inactivating, intra-molecular conformational change and may co-occur with polymerisation. However, the relationship between latency and polymerisation remained unexplored in the absence of a suitable probe. We have developed a novel monoclonal antibody specific for latent alpha(1)-antitrypsin and used it in combination with a polymer-specific antibody, to assess the association of both conformers in vitro, in disease and during augmentation therapy. In vitro kinetics analysis showed polymerisation dominated the pathway but latency could be promoted by stabilising monomeric alpha(1)-antitrypsin. Polymers were extensively produced in hepatocytes and a cell line expressing Z alpha(1)-antitrypsin but the latent protein was not detected despite manipulation of the secretory pathway. However, alpha(1)-antitrypsin augmentation therapy contains latent alpha(1)-antitrypsin, as did the plasma of 63/274 PiZZ individuals treated with augmentation therapy but 0/264 who were not receiving this medication (p < 10(-14)). We conclude that latent alpha(1)-antitrypsin is a by-product of the polymerisation pathway, that the intracellular folding environment is resistant to formation of the latent conformer but that augmentation therapy introduces latent alpha(1)-antitrypsin into the circulation. A suite of monoclonal antibodies and methodologies developed in this study can characterise alpha(1)-antitrypsin folding and conformational transitions, and screen methods to improve augmentation therapy. (C) 2014 The Authors. Published by Elsevier Ltd.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据